GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

GSK plcNYSE: GSK

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin narrows to 5.7%

Operating margin was 5.7% in Q2 FY2026, down 19.6 pp from a year earlier. On a trailing-twelve-month basis it was 20.7%, up 4.5 pp year over year. Over 3 fiscal years it widened by 3.6 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 16 analysts of 27.4% for the fiscal year ending Dec 2026, up from 25.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
5.7%-24.3 pp QoQ
Last fiscal yearDec 2025
25.5%+12.7 pp YoY
LTMJun 2026
20.7%+4.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-19.6 pp-1.3 pp+18.3 pp
1 year+12.7 pp+1.8 pp-10.9 pp
3 years+3.6 pp+2.5 pp-1.1 pp
5 years+3.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
25.5%
Year-over-year change
+12.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How GSK compares with its peers on the latest reported figures

  • GSK's LTM Jun 2026 operating margin of 20.7% is the 8th highest of the 10 companies compared; the peer median is 26.7%.
  • Its year-over-year change of +4.5 pp is the 3rd highest of 10, against a peer median of +0.3 pp.
  • Over three fiscal years its change of +3.6 pp compares with a peer median of +0.9 pp.
GSK Competitors Peer median
Operating Margin for GSK and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202649.7% +7.6 pp+15.2 pp
NVONovo Nordisk A/SLTM Jun 202643.1% -2.6 pp-1.0 pp
AMGNAmgen Inc.LTM Jun 202633.2% +9.7 pp-7.3 pp
NVSNovartis AGLTM Jun 202630.5% +0.3 pp+12.9 pp
PFEPfizer Inc.LTM Jun 202626.7% +0.6 pp-9.9 pp
JNJJohnson & JohnsonLTM Sep 202625.7% -0.4 pp+0.9 pp
AZNAstraZeneca PLCLTM Sep 202623.7% +1.6 pp+14.9 pp
GSKGSK plcLTM Jun 202620.7% +4.5 pp+3.6 pp
MRKMerck & Co., Inc.LTM Jun 202616.7% -16.9 pp+5.3 pp
SNYSanofiLTM Jun 202614.8% -3.6 pp-4.5 pp
Peer median (excluding GSK) 26.7%+0.3 pp+0.9 pp

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.7B29.32B30.33B31.38B32.67B
Cost of Revenue8.16B9.55B8.57B9.05B9.02B
Gross Profit16.53B19.77B21.76B22.33B23.65B
Gross Margin66.9%67.4%71.8%71.2%72.4%
Research & Development5.02B5.49B6.22B6.4B7.53B
Selling, General & Admin7.07B8.37B9.39B11.02B9.09B
Operating Expenses12.18B13.34B15.02B18.31B15.31B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
EBITDA6.49B8.6B9.08B6.67B10.4B
EBITDA Margin26.3%29.3%29.9%21.3%31.8%
Operating Income4.36B6.43B6.75B4.02B8.34B
Operating Margin17.6%21.9%22.2%12.8%25.5%
Interest Income28M64.27M40M67.39M56M
Interest Expense784M855.53M775M657.58M687M
Other Income / Expenses(758M)(805M)(681M)(544M)(937M)
Income Before Tax3.6B5.63B6.06B3.48B7.4B
Pre-Tax Margin14.6%19.2%20.0%11.1%22.7%
Income Tax Expense83M707M756M526M1.11B
Net Income4.39B14.96B4.93B2.58B5.72B
Net Margin17.8%51.0%16.2%8.2%17.5%
EPS (Basic)2.747.442.441.262.82
EPS (Diluted)2.707.322.401.242.78
Weighted Avg Shares1.6B2.01B2.03B2.04B2.03B
Weighted Avg Shares (Diluted)1.62B2.04B2.06B2.07B2.06B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.